Sonelokimab for Biologic-Naive Psoriatic Arthritis
Sonelokimab for Biologic-Naive Psoriatic Arthritis
MoonLake Immunotherapeutics AG ($MLTX)
Will this trial show a positive result on Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)?